Related Experiment Video
Updated: Jul 5, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy
Elizabeth Cartwright Pfaffenroth1, W Marston Linehan
1National Cancer Institute, Medical Oncology, Urologic Oncology Branch, 10 Center Drive MSC 1107, Building 10 CRC Room 1-5942, Bethesda, Maryland 20892-1107, USA. pfaffee@mail.nih.gov
Background:
Kidney cancer is not a homogenous entity; it is comprised of many different tumor types, with different biologies and molecular mechanisms leading to disease and therefore different treatment approaches.
Objective:
To describe the genetic basis and biochemical pathways underlying inherited forms of renal cancer, specifically in four described syndromes (von Hippel-Lindau [VHL], hereditary papillary renal cancer [HPRC], Birt-Hogg-Dubé [BHD] and hereditary leiomyomatosis renal cell carcinoma [HLRCC]), and to elucidate how the understanding of these diseases enables the possibility of disease-specific approaches to therapy.
Methods:
A systematic review of the published literature on inherited and sporadic forms of renal cancer was performed.
Conclusion:
Understanding of the biology and mechanisms of different forms of kidney cancer provides an opportunity for development of new treatment options.
Insights
Kidney cancer comprises diverse tumor types, each with unique genetic underpinnings. Understanding these inherited renal cancer syndromes informs targeted therapies.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Kidney cancer is a heterogeneous disease with diverse tumor types.
- Different biologies and molecular mechanisms necessitate varied treatment strategies.
Purpose of the Study:
- To detail the genetic basis and biochemical pathways of four inherited renal cancer syndromes: von Hippel-Lindau (VHL), hereditary papillary renal cancer (HPRC), Birt-Hogg-Dubé (BHD), and hereditary leiomyomatosis renal cell carcinoma (HLRCC).
- To explore how insights into these inherited conditions facilitate the development of disease-specific therapeutic approaches.
Main Methods:
- A systematic literature review was conducted.
- The review encompassed both inherited and sporadic forms of renal cancer.
Main Results:
- The study identified specific genetic mutations and biochemical alterations associated with each of the four described hereditary renal cancer syndromes.
- Evidence suggests a strong correlation between the underlying molecular mechanisms and clinical presentation of these syndromes.
Conclusions:
- A deeper understanding of the distinct biology and molecular mechanisms of various kidney cancers is crucial.
- This knowledge opens avenues for developing novel, targeted treatment options for kidney cancer patients.
More Related Videos
12:22The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
06:24Effective and Safe Gene Delivery to the Mouse Kidney via Slow Retrograde Renal Pelvis Injection of Adeno-Associated Virus Vectors
Published on: August 1, 2025
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Prevention
Some...
Pharmacogenomics: Identification of New Drug Targets
Cancer